A Randomized Double-Blind Placebo-Controlled Study Comparing Intracoronary Versus Intravenous Abciximab in Patients With ST-Elevation Myocardial Infarction Undergoing Transradial Rescue Percutaneous Coronary Intervention After Failed Thrombolysis
The risk and benefit ratio of glycoprotein IIb/IIIa inhibitors with dual oral antiplatelet therapy after failed thrombolysis and rescue percutaneous coronary intervention (PCI) is unclear. Using a randomized placebo-controlled, double-blind design, we compared intravenous (IV) and intracoronary (IC) abciximab delivery in 74 patients referred for rescue transradial PCI. The primary angiographic end points were the final thrombolysis in myocardial infarction flow and myocardial blush grades. Secondary end points included acute and 6-month outcomes using angiographic parameters, platelet aggregation parameters, cardiac biomarkers, cardiac magnetic resonance measurements (CMR) and clinical end points.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Olivier F. Bertrand, Éric Larose, Rodrigo Bagur, Frédéric Maes, Valérie Gaudreault, Bernard Noël, Gérald Barbeau, Jean-Pierre Déry, Charles Pirlet, Olivier Costerousse, Early Discharge After Transradial Stenting of Coronary Arteries in Acute Myocar Source Type: research
More News: Abciximab | Angiography | Angioplasty | Cardiology | Coronary Angioplasty | Heart | Heart Attack | Percutaneous Coronary Intervention | Study